Although rapid emergence of antibiotic-resistant mutants of Chlamydia trachomatis occurs when the organism is grown in subinhibitory concentrations of rifampin, no such mutants could be demonstrated when the organism was propagated under the same conditions in subinhibitory levels of the related drug rifabutin.
Rifampin, a potent inhibitor of DNA-dependent RNA polymerase, has been shown to be very active against Chlamydia trachomatis in a number of in vitro cell culture studies (2-5, 7). Becker (1) suggested that although a high incidence of rifampin-resistant mutants may occur in tubercular-and meningococcal-carrier states, the appearance of resistant C. trachomatis mutants may be less frequent because of the existence of two separate inhibitory sites on the rifampin molecule. However, subsequent studies have shown the rapid emergence of rifampin-resistant chlamydiae when passaged in the presence of subinhibitory levels of the drug (5, 6) .
More recently, several new rifamycin derivatives have become available, among which is rifabutin, a chemical congener of rifampin, which is synthesized by the chemical manipulation of rifamycin S. Studies have indicated that rifabutin may have activity against a wider range of organisms than rifampin; that when administered orally, rifabutin reaches much higher levels in tissues than in plasma and thus may be particularly useful for the treatment of intracellular infections; and that emergence of resistance to this new drug may be of much lower frequency than the emergence of resistance to rifampin (9) .
Our earlier work showed that there was no substantial difference in the MIC of rifampin when tested against 9 of the 15 C. trachomatis serovars (7). We were, however, able to demonstrate a stepwise increase in the MIC of rifampin for C. trachomatis which resulted in a 500-fold increase in resistance (MIC, 0.008 to 5.0 tig/ml) during 20 passages of the organism grown in the presence of subinhibitory levels of the drug. The purpose of our present study was to confirm the previous rifampin resistance findings in parallel with similar studies using rifabutin.
A stock of C. trachomatis serovar G was grown in mitomycin C-treated McCoy cells (8) V.g/ml) and rifabutin (0.009 pLg/ml) were remarkably similar (Table 1) . After five passages of C. trachomatis in 0.0008 p.g of rifampin per ml (0.1 MIC), the retested MIC of rifampin against the drug-treated organisms showed a 20-fold increase (0.16 ,ug/ml), whereas there was no increase in the MIC of rifabutin after C. trachomatis was passaged five times in 0.1 MIC of that drug. After 10 passages of C. trachomatis in 0.1 MIC of rifampin, the new MIC of rifampin when retested against the drug-treated organisms was >1.0 p.g/ml, representing an increase of over 100-fold. These rifampin-resistant mutants of C. trachomatis were stable when repassaged three to four times in the absence of the drug. When the rifabutin-treated chlamydiae were retested against rifabutin after 10 passages, no increase over the original MIC was observed (Table 1) . In cross-titration experiments, determination of the MIC of rifabutin against the rifampin-treated chlamydiae after 10 passages also showed an elevated MIC of 0.15 p.g/ml (i.e., a 20-fold increase). Conversely, the MIC of rifampin against rifabutin-treated organisms remained at 0.008 p.g/ml after both 5 and 10 passages in cell culture. This work substantiates our original findings and the findings of others that there is a rapid emergence of chlamydial resistance to rifampin. In addition, our data suggest 
